Q-omics provides the consensus-scored MIR3664 profile across patient tissues and cancer cell-line models. MIR3664 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR3664 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR3664 RNA expression shows 6,261 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, BRCA, and STAD as cancer lineages where MIR3664 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3664 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3664 survival associations across molecular data types. MIR3664 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3664 RNA expression–survival associations across cancer types. High MIR3664 expression shows unfavorable associations in KIRP, READ, ESCA, KIRC and LUSC, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR3664 RNA expression.
This table summarizes MIR3664 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3664. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3664 shows higher tumor expression in BRCA. The BRCA box plot shows higher MIR3664 RNA expression in tumor versus normal tissue (log2 FC = +0.201, t-test p = .016).
This table shows molecular features associated with MIR3664 in patient tissues and cancer cell lines. In patient samples, MIR3664 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
